NCT05736978View on ClinicalTrials.gov

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

March 15, 2027

Conditions
AMLMRD
Interventions
DRUG

Azacitidine

75mg/m2 d1-7

DRUG

Venetoclax

d1 100mg, d2 200mg, d3-28 400mg

DRUG

Selinexor

if MRD positive in C1D14, selinexor 60mg D15, D22

Trial Locations (4)

Unknown

NOT_YET_RECRUITING

Beizhan Hospital, Shanghai

NOT_YET_RECRUITING

Pla Navy Feature Medical Center, Shanghai

NOT_YET_RECRUITING

Shanghai Ruijin Hospital, Shanghai

RECRUITING

Shanghai Tong Ren hospital, Shanghai

All Listed Sponsors
lead

Shanghai Tong Ren Hospital

OTHER